Skip to main content

Table 1 Different types of mTORC2 targeted drugs

From: The role of RICTOR amplification in targeted therapy and drug resistance

Drug type Name Tumor or cell line Reference
ATP-competitive mTOR inhibitor CZ415 Head and neck squamous cell carcinoma (HNSCC), papillary thyroid carcinoma (Xie et al. 2018; Li et al. 2018)
Torin2 Adult T-cell leukemia/lymphoma, anaplastic thyroid cancer (Watanabe et al. 2016; Sadowski et al. 2015)
Intrahepatic cholangiocarcinoma
Neuroblastoma, breast cancer, osteosarcoma
(Zhang et al. 2017; Zhang et al. 2015; Liu et al. 2016)
PP242 Glioblastoma, ovarian cancer (Mecca et al. 2018; Kawata et al. 2018; Musa et al. 2016)
AZD8055 Adult T-cell leukemia (ATL), hepatocellular carcinoma, colon cancer, neuroblastoma (Kawata et al. 2018; Chen et al. 2018; Xu et al. 2018)
AZD2014 Diffuse intrinsic pontine glioma (DIPG), gastric cancer, anaplastic thyroid carcinoma (ATC), ovarian cancer (Kim et al. 2017a; Milosevic et al. 2018; Wong Te Fong et al. 2017; Flannery et al. 2018)
PI3K/mTOR inhibitor Dactolisib
Colon cancer, glioblastomas, breast cancer (Yu et al. 2016; Shi et al. 2018; Torki et al. 2017)
GSK1059615 Head and neck squamous cell carcinoma (HNSCC) (Xie et al. 2017a)
LY3023414 Esophageal Adenocarcinoma (Zaidi et al. 2017)
(SAR245409, XL765)
endometrial carcinoma (Yu et al. 2014; Inaba et al. 2015)
PQR309 brain tumor or CNS metastasis (Beaufils et al. 2017)
gedatolisib (PKI-587, PF05212384) breast, colon, lung, and glioma carcinoma (Venkatesan et al. 2010)
omipalisib (GSK2126458) breast carcinoma (Knight et al. 2010)
mTORC1/2 dual inhibitor CC-223 Hepatocellular carcinoma, colorectal cancer, head and neck squamous cell carcinoma (HNSCC) (Xie et al. 2017b; Wang et al. 2018a)
Ku0063794 Hepatocellular carcinoma (Kim et al. 2017b)
OSI027 Pancreatic cancer, colon cancer (Chen et al. 2015; Bhagwat et al. 2011; Zhi et al. 2015)
RES-529 (Palomid 529) Osteosarcoma, angiogenesis and vascular permeability, prostate cancer (Hu et al. 2018; Xue et al. 2008; Gravina et al. 2011)
WYE-687 Renal carcinoma, acute myeloid leukemia (AML) (Pan et al. 2017; Cheng et al. 2016)
WYE-354 Colon cancer, gallbladder cancer (Wang et al. 2016; Weber et al. 2015)